Day: March 27, 2025

• Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC) • Announced Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line HCC Pivotal Trial • Received FDA “Study May Proceed” letter for Phase 2 trial of TPST-1495 for the treatment of Familial Adenomatous Polyposis (FAP) BRISBANE, Calif., March 27, 2025 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the year ended 2024 and provided a corporate update. “2024 was another year filled with significant progress and milestone achievements that position Tempest for a successful future,”...

Company to Host Conference Call Today, March 27, at 4:30pm ET BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) — INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the year ended December 31, 2024 and provides a business update. Full Year 2024 and Recent Corporate Highlights   DN-TNF Platform Highlights (XPro1595, XPro™):Announced completion of enrollment for its Phase 2 trial on Friday, 27 September, 2024. This global, blinded, randomized Phase 2 trial (the “AD02 trial”) is focused on patients with Early Alzheimer’s Disease (AD) and biomarkers of elevated neuroinflammation. Final enrollment of 208 patients exceeded the trial’s target...

– Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four multiple ascending dose (MAD) cohorts; safety, pharmacokinetic, and pharmacodynamic data anticipated in Q4 2025 – Initiation of expansion into Phase 1b clinical trial in female OTC heterozygotes expected in Q2 2025 – Nomination of development candidate CMP-SYNGAP-01 to address SYNGAP1-related disorders; GLP toxicology studies expected to be initiated in 2025 CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) — CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced...

WINTER PARK, Fla., March 27, 2025 (GLOBE NEWSWIRE) — CTO Realty Growth (NYSE: CTO) (the “Company”) announced today that it will report its financial and operating results for the first quarter of 2025 after the market closes on Thursday, May 1, 2025. A conference call to discuss its financial and operating results is scheduled for Friday, May 2, 2025 at 9:00 AM ET. A live webcast of the call will be available on the Investor Relations page of the Company’s website at www.ctoreit.com or at the link provided in the event details below. To access the call by phone, please go to the registration link provided in the event details below and you will be provided with dial-in details.Event Details:Webcast: https://edge.media-server.com/mmc/p/4tgu64biRegistration: https://register-conf.media-server.com/register/BI4aedbe642bf743c8bf83e1370af52278   We...

HORSHAM, Pa., March 27, 2025 (GLOBE NEWSWIRE) — STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter and year ended December 31, 2024, and provides a corporate update. Fourth Quarter and Full-Year 2024 Financial HighlightsRevenue in the fourth quarter of 2024 was $9.6 million, up 10% from $8.7 million in the year-ago quarterGlobal net recurring XTRAC® revenue in the fourth quarter was $5.5 million vs. $5.4 million in the prior year period, with international growth of 13% more than offsetting a slight decline in the domestic market Average net revenue per domestic XTRAC® system increased to $5,906 (+6% YOY) on...

Webcast Today at 4:30 pm Eastern Time DENVER, March 27, 2025 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and year ended December 31, 2024, and provided business updates on key initiatives. “Our significant accomplishment in 2024 position us well for a transformational year in 2025,” said Eric Schlorff, SeaStar Medical CEO. “Last year, we not only received our first product approval for QUELIMMUNE and began our commercial launch, but we added 14 new clinical sites for our NEUTRALIZE AKI pivotal clinical trial, which has led to steady progress in enrollment with 94 of our anticipated 200 patients enrolled...

CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing regimen associated with exceptional overall survival (OS) with 66% and 58% of patients with mKRAS NSCLC alive at a landmark one-year and two-years, respectively, which exceeds the reported standard of careOzuriftamab vedotin (CAB-ROR2-ADC) demonstrated compelling anti-tumor activity in treatment-refractory, metastatic HPV-positive squamous cell carcinoma of the head and neck (SCCHN); a population which is poorly served by EGFR inhibitorsCash balance of $49mm at year-end 2024 with recent cost-reduction measures expected to further extend runway beyond key clinical readouts in 1H 2026Management to host conference call and webcast today...